Mitsui Chemicals, Inc.
Mitsui Chemicals, Inc. (MITUY) Financial Performance & Income Statement Overview
Analyze Mitsui Chemicals, Inc. (MITUY) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Mitsui Chemicals, Inc. (MITUY) Income Statement & Financial Overview
View the income breakdown for Mitsui Chemicals, Inc. MITUY across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $470.33B | $448.49B | $440.88B | $449.47B |
| Cost of Revenue | $369.87B | $351.67B | $349.62B | $349.71B |
| Gross Profit | $100.46B | $96.81B | $91.26B | $99.76B |
| Gross Profit Ratio | $0.21 | $0.22 | $0.21 | $0.22 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $77.50B | $74.11B | $71.01B | $72.73B |
| Operating Expenses | $77.50B | $74.11B | $71.01B | $72.73B |
| Total Costs & Expenses | $447.37B | $425.78B | $420.63B | $422.44B |
| Interest Income | $1.22B | $2.91B | $0.00 | $6.20B |
| Interest Expense | $6.96B | $0.00 | $4.91B | $4.13B |
| Depreciation & Amortization | $25.78B | $25.15B | $24.49B | $24.35B |
| EBITDA | $34.86B | $44.77B | $39.35B | $47.92B |
| EBITDA Ratio | $0.07 | $0.10 | $0.09 | $0.11 |
| Operating Income | $22.96B | $22.70B | $20.25B | $27.03B |
| Operating Income Ratio | $0.05 | $0.05 | $0.05 | $0.06 |
| Other Income/Expenses (Net) | -$20.85B | $1.13B | -$8.68B | $2.24B |
| Income Before Tax | $2.11B | $23.84B | $11.56B | $25.64B |
| Income Before Tax Ratio | $0.004 | $0.05 | $0.03 | $0.06 |
| Income Tax Expense | $9.32B | $6.26B | $4.46B | $8.98B |
| Net Income | -$5.47B | $15.48B | $4.34B | $17.89B |
| Net Income Ratio | -$0.01 | $0.03 | $0.010 | $0.04 |
| EPS | -$29.19 | $82.13 | $22.82 | $94.09 |
| Diluted EPS | -$29.19 | $82.13 | $22.82 | $94.09 |
| Weighted Avg Shares Outstanding | $187.34M | $188.50M | $190.17M | $190.13M |
| Weighted Avg Shares Outstanding (Diluted) | $187.34M | $188.50M | $190.17M | $190.13M |
The company's financials show resilient growth, with revenue advancing from $449.47B in Q1 2024 to $470.33B in Q4 2024. Gross profit remained healthy with margins at 21% in Q4 2024 compared to 22% in Q1 2024. Operating income hit $22.96B last quarter, sustaining a consistent 5% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $34.86B. Net income dropped to -$5.47B, while earnings per share reached -$29.19. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan